← Back to Search

Hormone Therapy

ERCP with inadvertent pancreatic cannulation for Endoscopic Retrograde Cholangiopancreatography (IDST Trial)

N/A

Waitlist Available

Led By Evan L Fogel, MD

Research Sponsored by Indiana University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 30 minutes

Awards & highlights

IDST Trial Summary

This trial is testing if a 30 minute intraductal secretin stimulation test can help determine if a person has a low likelihood of pancreatic pathology, compared to historical patients with suspected chronic pancreatitis.

IDST Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 30 minutes

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~30 minutes

This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 minutes for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Bicarbonate concentration of timed pancreatic juice

Secretory flow rates measured by volume

IDST Trial Design

1Treatment groups

Experimental Treatment

Group I: ERCP with inadvertent pancreatic cannulationExperimental Treatment1 Intervention

Subjects undergoing ERCP for a biliary indication in which inadvertent pancreatic cannulation occurs will undergo intraductal secretin testing per the study protocol.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Intraductal secretin test (IDST)

2017

N/A

~10

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Indiana UniversityLead Sponsor

979 Previous Clinical Trials

983,358 Total Patients Enrolled

Evan L Fogel, MDPrincipal InvestigatorIndiana University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How is Human Secretin for injection 16 mcg typically applied therapeutically?

"Human Secretin for injection 16 mcg is commonly prescribed to boost a mother’s lactation production. It may also help those with gastrinoma, secretory issues, and pancreatic exocrine dysfunction attain greater health outcomes."

Answered by AI

What is the upper limit for participants involved in this clinical trial?

"Affirmative, the information on clinicaltrials.gov confirms that this experiment is actively recruiting participants. It was initially advertised on September 1st 2017 and most recently updated August 18th 2022; they are looking for 36 individuals at a single medical centre."

Answered by AI

Is there presently an open call for participants of this experiment?

"Clinicaltrials.gov confirms that this research is actively recruiting participants, having first been posted on the 1st of September 2017 and last updated on August 18th 2022."

Answered by AI

What risks should patients be aware of when receiving a 16 mcg injection of Human Secretin?

"Considerable clinical evidence supports the safety of Human Secretin for injection 16 mcg, so it has been issued a score of 3."

Answered by AI

Is this a pioneering trial, or have there been similar ones before?

"Currently, 3 active clinical trials involving Human Secretin for injection 16 mcg are taking place across 9 cities and 1 nation. The initial investigation of this drug commenced in 2014 under the sponsorship of ChiRhoClin, Inc., with 7000 participants involved in its Phase 3 approval process. Since then, 11 additional studies have been concluded successfully."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Intraductal Secretin Stimulation Test: What Is the Proper Collection Time?

Evan Fogel 2017. "Intraductal Secretin Stimulation Test: What Is the Proper Collection Time?". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03263481.